ClinicalTrials.gg
CompletedNCT02695420Updated Jul 27, 2021Results posted

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

A Phase 2 interventional study of 25 mg Omecamtiv Mecarbil and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics. Completed at 32 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
6th of 14
81 · median 48
Started
2016
the only one that year
Phase 2
7 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 2, and was the 10th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

  • To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction
  • To evaluate the safety and tolerability of oral omecamtiv mecarbil
Read the detailed description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • Heart Failure
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or female ≥ 20 years and ≤ 85 years of age
  • History of chronic stable heart failure (HF) with reduced , defined as requiring treatment for HF for a minimum of 4 weeks prior to screening
  • Treated for HF with optimal pharmacological therapy
  • Left ventricular ejection fraction ≤ 40% at screening

Exclusion criteria

Exclusion Criteria:

  • Severe uncorrected valvular heart disease
  • Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or congenital heart disease
  • Acute myocardial infarction, unstable angina, or persistent angina at rest within 30 days prior to randomization
  • Systolic blood pressure (BP) > 160 mmHg or \< 90 mmHg, or diastolic BP > 90 mmHg, or heart rate (HR) > 110 beats per minute (bpm) or HR \< 50 bpm
  • Estimated (eGFR) \< 30 mL/min/1.73 m\^2
  • Total (TBL) ≥ 2x (ULN), or (ALT) or aspartate aminotransferase (AST) ≥ 3x ULN Other Exclusion Criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Placebo comparator
    Placebo BID

    Participants will receive placebo BID.

    Drug: 25 mg Omecamtiv Mecarbil

  • Experimental
    25 mg Omecamtiv Mecarbil BID

    Participants will receive 25 mg omecamtiv mecarbil BID.

    Drug: Placebo

  • Experimental
    37.5 mg Omecamtiv Mecarbil BID Target Dose

    Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.

    Drug: 25 mg Omecamtiv Mecarbil · Drug: 37.5 mg Omecamtiv Mecarbil

  • Experimental
    50 mg Omecamtiv Mecarbil BID Target Dose

    Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.

    Drug: 25 mg Omecamtiv Mecarbil · Drug: 50 mg Omecamtiv Mecarbil

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time

    Time frame: Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)

  2. PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)

    Time frame: Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose

Secondary outcomes

  1. Change From Baseline at Week 16 in Systolic Ejection Time (SET)

    LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.

    Time frame: Baseline, Week 16 (Day 112)

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence. Serious AEs are defined as AEs that meets at least 1 of the following serious criteria: fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important serious event. AEs are graded as: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. TEAEs are defined as events occurring after the first dose of study drug.

    Time frame: From first dose of study drug up to Week 20 (Day 140 + 3 days)

07

Results

Posted Jan 31, 2020

Participant flow

Participants were enrolled at 31 research centers in Japan from 14 April 2016 to 16 December 2016.

Participant flow — Overall Study
MilestonePlacebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
Started21211920
Completed21201920
Not completed0100
Withdrew: Death0100

Outcome measures

PrimaryPharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time
Time frame:
Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time
ng/mLOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
Week 2239 ± 106179 ± 77.1208 ± 61.6
Week 4222 ± 63.5196 ± 44209 ± 61.9
Week 12217 ± 66.1228 ± 56.9282 ± 120
Week 16206 ± 84.5244 ± 67.7292 ± 118
PrimaryPK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)
Time frame:
Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose
Reported as:
Mean · hr*ng/mL
PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)
hr*ng/mLOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)1850 ± 5631850 ± 3832360 ± 465
SecondaryChange From Baseline at Week 16 in Systolic Ejection Time (SET)

LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.

Time frame:
Baseline, Week 16 (Day 112)
Reported as:
Least squares mean · msec
Change From Baseline at Week 16 in Systolic Ejection Time (SET)
msecPlacebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
Change From Baseline at Week 16 in Systolic Ejection Time (SET)-1.7 ± 4.720.5 ± 4.927.6 ± 5.423.8 ± 5.2
Statistical analysis
  • Placebo BID vs Omecamtiv Mecarbil 25 mg BID · Repeated Measures Model · p = 0.0008 · Treatment difference: 22.1 · 95% CI 9.6 to 34.7
  • Placebo BID vs Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose · Repeated measures model · p = < 0.0001 · Treatment difference: 29.3 · 95% CI 16.3 to 42.3
  • Placebo BID vs Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose · Repeated measures model · p = 0.0002 · Treatment difference: 25.5 · 95% CI 12.6 to 38.4
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence. Serious AEs are defined as AEs that meets at least 1 of the following serious criteria: fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, other medically important serious event. AEs are graded as: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. TEAEs are defined as events occurring after the first dose of study drug.

Time frame:
From first dose of study drug up to Week 20 (Day 140 + 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlacebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
All TEAEs14101012
Grade >= 2 TEAEs10667
Grade >= 3 TEAEs3412
Grade >= 4 TEAEs0100
Serious AEs3413
TEAEs Leading to Withdrawal of Study Drug0210
Fata Adverse Events0100

Adverse events

Collected over From first dose of study drug up to Week 20 (Day 140 + 3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BID0/21 (0%)3/21 (14.3%)10/21 (47.6%)
Omecamtiv Mecarbil 25 mg BID1/21 (4.8%)4/21 (19%)8/21 (38.1%)
Omecamtiv Mecarbil 25 mg to 37.5 mg BID Target Dose0/19 (0%)1/19 (5.3%)10/19 (52.6%)
Omecamtiv Mecarbil 25 mg to 50 mg BID Target Dose0/20 (0%)3/20 (15%)11/20 (55%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
PneumoniaInfections and infestations1/210/211/190/20
Angina pectorisCardiac disorders0/210/210/191/20
Cardiac failureCardiac disorders1/211/210/191/20
Cardiac failure chronicCardiac disorders0/211/210/191/20
Vascular stent restenosisGeneral disorders0/210/210/191/20
Cardiac failure congestiveCardiac disorders0/211/210/190/20
Cardiac ventricular thrombosisCardiac disorders1/210/210/190/20
Cardio-respiratory arrestCardiac disorders0/211/210/190/20
Ventricular fibrillationCardiac disorders0/211/210/190/20
Hepatic function abnormalHepatobiliary disorders0/211/210/190/20
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlacebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target Dose
Viral upper respiratory tract infectionInfections and infestations4/211/214/194/20
PeriodontitisInfections and infestations0/211/212/190/20
HypotensionVascular disorders0/210/212/190/20
ArthralgiaMusculoskeletal and connective tissue disorders0/210/210/192/20
DizzinessNervous system disorders1/211/210/192/20
Iron deficiency anaemiaBlood and lymphatic system disorders0/212/210/190/20
InfluenzaInfections and infestations1/212/210/190/20
DehydrationMetabolism and nutrition disorders0/212/210/190/20
DermatitisSkin and subcutaneous tissue disorders0/212/210/190/20
BradycardiaCardiac disorders0/210/211/190/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target DoseTotal
Mean64.6 ± 11.566.9 ± 10.363.6 ± 10.866.5 ± 12.265.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target DoseTotal
Female930113
Male1218191968
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target DoseTotal
Asian2121192081
Other00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target DoseTotal
Japanese2121192081
Other00000
Atrial Fibrillation/Flutter at Randomization
Atrial Fibrillation/Flutter at Randomization(participants)Placebo BIDOmecamtiv Mecarbil 25 mg BIDOmecamtiv Mecarbil 25 mg to 37.5 mg BID Target DoseOmecamtiv Mecarbil 25 mg to 50 mg BID Target DoseTotal
Present443415
Absent1717161666
08

Study locations

32 sites
  • Research Site
    Kasugai-shi, Aichi 486-8510, Japan
  • Research Site
    Kasugai-shi, Aichi 487-0016, Japan
  • Research Site
    Nagoya-shi, Aichi 454-8509, Japan
  • Research Site
    Asahi-shi, Chiba 289-2511, Japan
  • Research Site
    Chiba-shi, Chiba 260-8606, Japan
  • Research Site
    Imabari-shi, Ehime 799-1592, Japan
  • Research Site
    Chikushino-shi, Fukuoka 818-8516, Japan
  • Research Site
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • Research Site
    Fukuoka-shi, Fukuoka 815-8588, Japan
  • Research Site
    Hakodate-shi, Hokkaido 041-8512, Japan
  • Research Site
    Sapporo, Hokkaido 060-8648, Japan
  • Research Site
    Amagasaki-shi, Hyogo 660-8550, Japan
  • Research Site
    Kawanishi-shi, Hyogo 666-0125, Japan
  • Research Site
    Takarazuka-shi, Hyogo 665-0873, Japan
  • Research Site
    Kanazawa-shi, Ishikawa 920-8650, Japan
  • Research Site
    Nankoku-shi, Kochi 783-8505, Japan
  • Research Site
    Oita-shi, Oita 870-0192, Japan
  • Research Site
    Okayama-shi, Okayama 702-8055, Japan
  • Research Site
    Kishiwada-shi, Osaka 596-8522, Japan
  • Research Site
    Osaka-shi, Osaka 532-0003, Japan
  • Research Site
    Osaka-shi, Osaka 550-0012, Japan
  • Research Site
    Osaka-shi, Osaka 559-0012, Japan
  • Research Site
    Suita-shi, Osaka 565-0871, Japan
  • Research Site
    Saga-shi, Saga 840-8571, Japan
  • Research Site
    Saitama-shi, Saitama 330-8503, Japan
  • Research Site
    Wako-shi, Saitama 351-0102, Japan
  • Research Site
    Sunto-gun, Shizuoka 411-8611, Japan
  • Research Site
    Chiyoda-ku, Tokyo 101-8309, Japan
  • Research Site
    Itabashi-ku, Tokyo 173-0015, Japan
  • Research Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Research Site
    Meguro-ku, Tokyo 152-8902, Japan
  • Research Site
    Shinagawa-ku, Tokyo 141-0001, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Apr 2017, 11 months.

Results were first posted in Jan 2020, 2 years 9 months after primary completion. A results delay was requested in Feb 2018.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2016
First posted
Mar 1, 2016
StartActual
Apr 14, 2016
Primary completionActual
Apr 6, 2017
CompletionActual
May 8, 2017
Results delay requested
Feb 5, 2018
Results first posted
Jan 31, 2020
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02695420
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Mar 1, 2016
Start date
Apr 14, 2016
Primary completion
Apr 6, 2017
Completion
May 8, 2017
Results posted
Jan 31, 2020
Last update
Jul 27, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion